Lawrence B. Cohen’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-8,482
| Closed | -$588K | – | 23 |
|
|
2023
Q3 | $588K | Sell |
8,482
-160
| -2% | -$12.9K | 0.4% | 48 |
|
|
2023
Q2 | $815K | Sell |
8,642
-430
| -5% | -$37.4K | 0.52% | 53 |
|
|
2023
Q1 | $751K | Sell |
9,072
-1,209
| -12% | -$95K | 0.5% | 50 |
|
|
2022
Q4 | $767K | Sell |
10,281
-900
| -8% | -$69.4K | 0.4% | 68 |
|
|
2022
Q3 | $924K | Sell |
11,181
-5,288
| -32% | -$509K | 0.71% | 52 |
|
|
2022
Q2 | $1.57M | Sell |
16,469
-1,622
| -9% | -$168K | 1.12% | 44 |
|
|
2022
Q1 | $2.13M | Buy |
18,091
+64
| +0.4% | +$7.18K | 1.26% | 39 |
|
|
2021
Q4 | $2.33M | Sell |
18,027
-7,432
| -29% | -$867K | 0.91% | 47 |
|
|
2021
Q3 | $2.88M | Sell |
25,459
-3,347
| -12% | -$382K | 1.52% | 27 |
|
|
2021
Q2 | $2.98M | Sell |
28,806
-2,360
| -8% | -$222K | 1.52% | 30 |
|
|
2021
Q1 | $2.61M | Sell |
31,166
-1,235
| -4% | -$104K | 1.41% | 30 |
|
|
2020
Q4 | $2.96M | Sell |
32,401
-1,316
| -4% | -$109K | 1.64% | 25 |
|
|
2020
Q3 | $2.69M | Sell |
33,717
-984
| -3% | -$76.8K | 1.64% | 23 |
|
|
2020
Q2 | $2.4M | Sell |
34,701
-348
| -1% | -$24.7K | 1.6% | 25 |
|
|
2020
Q1 | $2.2M | Sell |
35,049
-2,094
| -6% | -$151K | 1.73% | 24 |
|
|
2019
Q4 | $2.89M | Buy |
37,143
+657
| +2% | +$51.3K | 1.71% | 25 |
|
|
2019
Q3 | $2.67M | Sell |
36,486
-10,593
| -23% | -$744K | 1.75% | 25 |
|
|
2019
Q2 | $2.9M | Sell |
47,079
-6,066
| -11% | -$367K | 2.01% | 20 |
|
|
2019
Q1 | $3.39M | Sell |
53,145
-13,605
| -20% | -$776K | 2.39% | 16 |
|
|
2018
Q4 | $3.41M | Sell |
66,750
-2,583
| -4% | -$131K | 2.65% | 13 |
|
|
2018
Q3 | $4.02M | Sell |
69,333
-20,625
| -23% | -$1.01M | 2.73% | 11 |
|
|
2018
Q2 | $4.37M | Sell |
89,958
-29,727
| -25% | -$1.39M | 3.12% | 8 |
|
|
2018
Q1 | $5.57M | Sell |
119,685
-20,310
| -15% | -$882K | 3.73% | 5 |
|
|
2017
Q4 | $5.26M | Sell |
139,995
-3,240
| -2% | -$119K | 3.34% | 7 |
|
|
2017
Q3 | $5.22M | Sell |
143,235
-15,780
| -10% | -$602K | 3.4% | 6 |
|
|
2017
Q2 | $6.27M | Sell |
159,015
-25,860
| -14% | -$944K | 4.01% | 3 |
|
|
2017
Q1 | $5.8M | Sell |
184,875
-26,055
| -12% | -$816K | 3.57% | 9 |
|
|
2016
Q4 | $6.59M | Sell |
210,930
-20,640
| -9% | -$669K | 4% | 4 |
|
|
2016
Q3 | $9.31M | Sell |
231,570
-10,560
| -4% | -$398K | 5.54% | 2 |
|
|
2016
Q2 | $8.05M | Sell |
242,130
-28,878
| -11% | -$988K | 4.82% | 2 |
|
|
2016
Q1 | $7.97M | Sell |
271,008
-2,880
| -1% | -$79.5K | 5.22% | 2 |
|
|
2015
Q4 | $7.21M | Sell |
273,888
-41,400
| -13% | -$1.08M | 4.9% | 3 |
|
|
2015
Q3 | $7.47M | Sell |
315,288
-4,950
| -2% | -$119K | 5.2% | 2 |
|
|
2015
Q2 | $7.6M | Sell |
320,238
-10,200
| -3% | -$230K | 4.8% | 3 |
|
|
2015
Q1 | $7.85M | Sell |
330,438
-15,660
| -5% | -$351K | 4.79% | 3 |
|
|
2014
Q4 | $7.35M | Sell |
346,098
-372
| -0.1% | -$7.47K | 4.42% | 4 |
|
|
2014
Q3 | $5.9M | Sell |
346,470
-6,450
| -2% | -$102K | 3.89% | 7 |
|
|
2014
Q2 | $5.05M | Buy |
352,920
+7,230
| +2% | +$98K | 3.31% | 9 |
|
|
2014
Q1 | $4.27M | Buy |
345,690
+2,550
| +0.7% | +$29.4K | 2.95% | 15 |
|
|
2013
Q4 | $3.76M | Buy |
343,140
+73,080
| +27% | +$824K | 2.68% | 18 |
|
|
2013
Q3 | $3.13M | Buy |
+270,060
| New | +$3.16M | 2.37% | 20 |
|
Other funds holding EW
Lawrence B. Cohen's EW Position: Q4 2023 in Review
Lawrence B. Cohen sold out of Edwards Lifesciences (EW) in Q4 2023, closing a stake of 8,482 shares — an estimated $588K sold.
Lawrence B. Cohen first reported a position in EW in Q3 2013 and held it in 41 quarters. The position peaked at $9.31M in Q3 2016. 1,244 funds tracked by Wall St. Rank hold EW as of Q4 2023.
- Lawrence B. Cohen reported no remaining Edwards Lifesciences position as of Q4 2023 after selling out during the quarter.
- Lawrence B. Cohen sold 8,482 Edwards Lifesciences shares in Q4 2023, an estimated $588K.
- Lawrence B. Cohen first reported a position in Edwards Lifesciences in Q3 2013 and held it in 41 quarters.
- Lawrence B. Cohen's Edwards Lifesciences position peaked at $9.31M in Q3 2016.
- 1,244 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2023.
Based on Lawrence B. Cohen's 13F filing for Q4 2023, filed 9 Feb 2024.